Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Central South University

Status

Enrolling

Conditions

Major Depressive Disorder

Bipolar Disorder

Treatments

Drug: Quetiapine

Drug: Vortioxetine

Study type

Observational

Funder types

Other

Identifiers

NCT05840861

PCT 202007

Details and patient eligibility

About

Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD. fMRI and NODDI are also used to evaluate the function or neurite condition at baseline and 8 week

Enrollment

59 estimated patients

Sex

All

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Meet DSM-V criteria for a current depressive episode.
Being first-episode patients who were medication-naïve;
Score >17 on 17-item Hamilton Depression Rating Scale (HDRS), score >22 on Montgomery-Asberg Depression Rating Scale (MADRS), and score <6 on Young Mania Rating Scale (YMRS).
Age 18 to 35.
Able to give written informed consent.

Exclusion criteria

Have a current or past significant medical, neurological or metabolic disorder or head injury
Have active, significant suicidal ideation or past suicide attempts
Have implanted metallic devices or any MR contraindications
Are women who are pregnant or breastfeeding
Met DSM-5 criteria for substance use disorder
Met DSM-5 criteria for any current Axis I diagnosis (except Generalized Anxiety Disorder)
Are MDD patients present with delusions and/or hallucinations